Free tool
FAERS Monitor: Livtencity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215596 or its brand name (Livtencity, Maribavir). Reports on generic versions are filed under their own applications.
Reports
2,469
Serious
2,128
86% of reports
Hospitalization
1,124
Death reported
536
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death317
- dysgeusia268
- taste disorder229
- hospitalisation223
- off label use206
- cytomegalovirus infection189
- drug ineffective187
- drug resistance184
- fatigue176
- cytomegalovirus infection reactivation156
- product use issue136
- diarrhoea133
- viral load increased128
- nausea115
- cytomegalovirus viraemia88
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 12 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 17 |
| 2022 | 497 |
| 2023 | 514 |
| 2024 | 563 |
| 2025 | 556 |
| 2026 | 282 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,690 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus infection reactivationSignal | 156 | 311.8 | 267.1 | 46,334 |
| viral load increasedSignal | 128 | 290.4 | 244.6 | 35,429 |
| cytomegalovirus viraemiaSignal | 88 | 171.9 | 139.7 | 14,492 |
| cytomegalovirus infectionSignal | 189 | 98.0 | 85.4 | 17,853 |
| taste disorderSignal | 229 | 97.2 | 85.9 | 21,493 |
| drug resistanceSignal | 184 | 61.5 | 53.4 | 10,817 |
| dysgeusiaSignal | 268 | 30.8 | 27.5 | 7,707 |
| hospitalisationSignal | 223 | 12.4 | 10.9 | 2,335 |
| product use issueSignal | 136 | 6.2 | 5.2 | 589 |
| deathSignal | 317 | 3.1 | 2.8 | 478 |
| off label useSignal | 206 | 2.0 | 1.8 | 107 |
| fatigue | 176 | 1.9 | 1.7 | 80 |
| diarrhoea | 133 | 1.8 | 1.5 | 44 |
| nausea | 115 | 1.2 | 1.0 | 5 |
| drug ineffective | 187 | 1.2 | 1.1 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.